Brentuximab vedotin in combination with chemotherapy for the treatment of patients with stage 3 or 4 CD30 positive Hodgkin lymphoma

NICE

7 May 2025 - Brentuximab vedotin, when used in combination with doxorubicin hydrochloride, dacarbazine and vinblastine sulphate is recommended as an option for the first-line treatment of adults with stage 3 or 4 CD30 positive Hodgkin lymphoma.

It can only be used if Takeda provides it according to the commercial arrangement.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder